Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 499 clinical trials
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Acute myeloid leukemia is a malignant disorder characterized by the rapid, uncontrolled proliferation of malignant clonal hematopoietic stem cells that accumulate as immature, undifferentiated cells (blasts) in the bone marrow and circulation.

myeloid leukemia
leukemia
blood cell count
hydroxyurea
azacitidine
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.

  • 0 views
  • 30 Apr, 2025
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the relapse rate but has some fatal side effects such as irreversible damage to normal internal …

crenolanib
midostaurin
gilbert's syndrome
intensity-modulated radiation therapy
rapid plasma reagin measurement
  • 0 views
  • 16 Feb, 2024
  • 1 location
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

This phase II trial studies how well decitabine with ruxolitinib or fedratinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, …

cancer care
gilbert's syndrome
secondary myelofibrosis
hemolysis
leukapheresis
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation

Venetoclax is a drug approved to treat Acute Myeloid Leukemia. All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label.

  • 0 views
  • 16 Feb, 2024
  • 3 locations
The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project

There is currently lack of collaborative data on the epidemiology, clinicopathologic features and treatment outcome of newly diagnosed and relapsed APL in Asia. In addition, there is lack of data comparing oral- As2O3-based regimens with other treatment approaches, including intravenous As2O3,in the frontline or relapsed setting. With the long-term data …

acute myeloid leukemia
acute promyelocytic leukemia
arsenic
rara translocation
leukemia
  • 0 views
  • 16 Feb, 2024
  • 1 location
Quality of Life Model for Older Patients With AML

The purpose of this study is to describe the differences in quality of life (QOL) among newly diagnosed patients diagnosed with acute myeloid leukemia (AML) to help design a patient decision-making QOL model for aligning patients' choice of treatment with what matters the most to them.

myeloid leukemia
acute myeloid leukemia
leukemia
  • 0 views
  • 05 Aug, 2020
AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

In this study, the investigators will explore the feasibility of ex vivo drug screening to predict sensitivity to chemotherapy resistance and to identify novel synergy between chemotherapies.

myelodysplastic syndrome
gemtuzumab ozogamicin
midostaurin
acute myeloid leukemia
idarubicin
  • 0 views
  • 16 Feb, 2024
  • 1 location
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice

melanoma of the skin
cancer
basal cell carcinoma of the skin
  • 0 views
  • 05 Aug, 2020